Im­muno­Gen gets $25M up­front for ADC ther­a­py; mi­Ra­gen adds Eu­ro­pean or­phan drug des­ig­na­tion; Pierre Fab­re buys some pre­clin­i­cal im­munother­a­pies

→  The Eu­ro­pean Com­mis­sion grant­ed or­phan drug des­ig­na­tion to mi­Ra­gen’s $MGEN MRG-106 for the treat­ment of cu­ta­neous T-cell lym­phoma (CT­CL). “The Eu­ro­pean or­phan drug des­ig­na­tion for MRG-106 is an­oth­er reg­u­la­to­ry mile­stone which we be­lieve fur­ther val­i­dates the med­ical need for nov­el ther­a­pies in the treat­ment of CT­CL,” said mi­Ra­gen pres­i­dent and CEO, William Mar­shall. It earned the FDA’s own or­phan des­ig­na­tion for treat­ment of my­co­sis fun­goides—the most com­mon sub­type of CT­CL—ear­li­er this year. The Boul­der, CO-based mi­croR­NA biotech found its way in­to the pub­lic mar­kets last No­vem­ber, re­verse merg­ing with strug­gling Sig­nal Ge­net­ics and gain­ing a $40 mil­lion round to fi­nance clin­i­cal work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.